Pseudomonas Aeruginosa
With a high resistance to antibodies, Pseudomonas Aeruginosa (PA), a Gram-Negative Bacteria (GNB), has become a major global health concern. As an opportunistic pathogen, PA puts immunocompromised individuals at particularly severe risk.
An Ever-Present Risk
in Healthcare Facilities
Spread through ingestion and direct contact with contaminated surfaces such as food, disinfectants, respiratory equipment, sinks, and beyond, PA is primarily a nosocomial pathogen that originates and spreads in hospital settings.
With a .4% incidence rate at US hospitals based on CDC data, PA comprises over 10% of all hospital-related infections and is the fourth most common nosocomial pathogen.
The Common Culprit
of Systemic Infections
With a rapid incubation period of 24 to 72 hours, PA is the common culprit behind countless infections throughout the body, including within the respiratory, digestive, and skeletal systems. These infections are more prevalent and severe in individuals with cancer, AIDS, and immunodeficiencies such as cystic fibrosis.
In light of PA’s resistance to antibiotics, Pharmotech SA has discovered the use of CBD to potentially prevent and treat PA. This patented advancement is designed to decontaminate medical materials and hospital rooms. With extensive R&D rooted in natural, active ingredients, Pharmotech SA is unveiling new possibilities for hospital and veterinary applications worldwide.
(1).jpg)